1833 (1833) Fair Value & Analysis

Healthcare · Market cap HK$15.0B

1 1833 1833 · HK

PriceHK$7.07

Fair ValueHK$4.01

Upside-43.3%

Quality46/100

Watch 1833 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$2.93 – HK$4.38

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −24.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$6.58 – HK$23.14 · fair‑value band HK$2.93 – HK$4.38 · the HK$7.07 price screens above the HK$4.01 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1833 (1833) currently trades at HK$7.07, while our model-based Fair Value estimate is HK$4.01 — implying the stock looks roughly 43.3% overvalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 1833 generated revenue of HK$5.5B at a net margin of 6.9%. Revenue grew 9.3% year over year. It earns a return on equity of 5.6%. The balance sheet holds a net cash position of HK$2.4B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$5.5B

Revenue growth (YoY) +9.3%

Net margin 6.9%

Return on equity 5.6%

Free cash flow HK$392M FY2025

P/E ratio 33.7

More key figures

Operating margin 4.9%

EPS (TTM) HK$0.0700

EPS growth (YoY) +378%

Net cash HK$2.4B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1833 reported revenue of HK$5.5B in FY2025 versus HK$7.3B in FY2021, a compound −7.1%/yr. Reported net income was HK$380M in FY2025.

Revenue −7.1%/yr

FY21 HK$7.3B

FY22 HK$6.2B

FY23 HK$4.7B

FY24 HK$4.8B

FY25 HK$5.5B

Net income

FY21 −HK$1.5B

FY22 −HK$636M

FY23 −HK$323M

FY24 HK$81.4M

FY25 HK$380M

Is 1833 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$153.16	$183.66	+20%
Pro Medicus Limited PME	A$165.64	A$28.02	-83%
BrightSpring Health Services, Inc BTSG	$66.84	$21.63	-68%
Tempus AI, Inc TEM	$48.61	$12.67	-74%
HealthEquity, Inc HQY	$84.61	$79.57	-6%
M3, Inc MTHRY	$5.21	$7.47	+43%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1833 (1833) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$4.01 versus a price of HK$7.07 — about −43% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1833?

Our model-based fair value for 1833 is HK$4.01 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$7.07.

What is the quality score of 1833?

1833 has a Quality Score of 46/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1833 (1833)?

1833 reported trailing-twelve-month revenue of about HK$5.5B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1833?

The net profit margin of 1833 is about 6.9%, meaning it keeps roughly 6.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.